The number of notified cases of invasive pneumococcal disease (IPD) in the first quarter of 2019 was lower than the previous quarter, but greater than the first quarter of 2018. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by the 13vPCV across all age groups, however more recently this decline is no longer evident. Over this period the number of cases due to the eleven serotypes additionally covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV) and also those serotypes not covered by any available vaccine has been increasing steadily across all age groups ( Figure 1 ).
a slight increase compare to the fourth quarter of 2018 (48%; 37/77) (Figure 2 ). The most frequent serotypes among cases aged less than 5 years this quarter were serotype 19F (16%; 8/29) and 3 (13%; 6/29), both of which are included in the 13vPCV. Of the 17 cases aged less than 5 years with 13vPCV serotypes, 9 cases were fully vaccinated and considered to be 13vPCV failures. These 13vPCV failures were due to serotypes 3 (n=5) and 19F (n=4) ( Table 4) .
Among Indigenous Australians aged 50 years and over, there were 9 cases of IPD reported this quarter. Of those cases with a reported serotype (n=8), 3 (38%) were due to a serotype included in the 23vPPV, and overall there was no particular serotype dominant this quarter (   Figure 3 ). The proportion of cases with a reported serotype that were due to a serotype included in the 23vPPV is almost half of the proportion reported last quarter (72%; 13/18), and in the first quarter of 2018 (71%; 10/14).
Among non-Indigenous Australians ii aged 65 years and over there were 84 cases of IPD reported this quarter. The number of notified cases of IPD in this population group were 50% lower compared to the number of cases reported in the previous quarter (n=166) and 11% lower than the number reported in the first quarter of 2018 (n=93). Of those cases with a reported serotype (n=76), 61% (46/76) were due to a serotype included in the 23vPPV (Figure 4 ). This was similar to the proportions in the previous quarter (63%; 101/161) and the first quarter of 2018 (56%; 46/82). For this quarter, serotype 3 (n=12) was the most common serotype reported for this population group, followed by serotypes 19F (n=8) and 6C (n=6). Serotypes 3 and 19F are included in the 23vPPV.
During this quarter there were 13 deaths attributed to a variety of IPD serotypes. Eight (62%) of the cases had a serotype covered by currently available pneumococcal vaccines, four were due to a non-vaccine serotype, and one was reported as being untyped. One of the reported deaths this quarter was reported in an Indigenous Australian. The median age of those cases reported to have died this quarter was 72 years (range 0 to 87 years).
ii Non-Indigenous Australians includes cases reported with an Indigenous status of non-Indigenous, not stated, blank or unknown. * Indigenous status completeness is defined as the reporting of a known Indigenous status, excluding the reporting of not stated or unknown Indigenous status. † Targeted groups for follow-up by almost all jurisdictions and public health units are cases aged less than 5 years and 50 years and over. ǂ Serotype completeness is the proportion of all cases of invasive pneumococcal disease that were reported with a serotype or reported as nontypable. Incomplete serotype data can occur in cases when (i) no isolate was available as diagnosis was by polymerase chain reaction and no molecular typing was attempted or was not possible due to insufficient genetic material; (ii) the isolate was not referred to the reference laboratory or was not viable; (iii) typing was pending at the time of reporting, or no serotype was reported by the notifying jurisdiction to the National Notifiable Diseases Surveillance System. 
Notes
The data in this report are provisional and subject to change as laboratory results and additional case information become available. More detailed data analysis of IPD in Australia and surveillance methodology are described in the IPD annual report series published in Communicable Diseases Intelligence.
In Australia, pneumococcal vaccination is recommended as part of routine immunisation for children, individuals with specific underlying conditions associated with increased risk of IPD and older Australians. More information on the scheduling of the pneumococcal vaccination can be found on the Immunise Australia Program website (www.immunise.health.gov.au).
In this report, a 'vaccine failure' is reported when a child aged less than 5 years is diagnosed with IPD due to a serotype found in the 13vPCV and they have received 3 primary scheduled doses of 13vPCV at least 2 weeks prior to disease onset with at least 28 days between doses of vaccine.
There are 3 pneumococcal vaccines available in Australia, each targeting multiple serotypes ( Table 5 ). Note that in this report serotype analysis is generally grouped according to vaccine composition.
Follow-up of all notified cases of IPD is undertaken in all states and territories except New South Wales and Victoria who conduct targeted follow-up of notified cases aged under 5 years, and 50 years or over for enhanced data. Followup of notified cases of IPD in Queensland is undertaken in all areas except Metro South and Gold Coast Public Health Units who conduct targeted follow-up of notified cases for those aged under 5 years only. However, in these areas where targeted case follow-up is undertaken, some enhanced data may also be available outside these targeted age groups. 
